5/2
Penn in the News
A round-up of Penn mentions in local, national, and international media.
Filter Stories
Penn In the News
Biden’s student loan repayment plan is being challenged. Here’s what to know
Kent Smetters of the Wharton School attributes $235 billion of the cost of the SAVE loan repayment plan to its increased generosity relative to existing plans.
Penn In the News
Report: Biden’s new debt relief plan estimated to cost $84 billion
According to economists at the Penn Wharton Budget Model, President Biden’s new plan to forgive some or all student loans for 26 million Americans would cost about $84 billion over 10 years.
Penn In the News
Bridging Blocks has Philadelphians focused on dispelling myths around immigration
Exequiel Hernandez of the Wharton School says that immigrants are net positive contributors to everything that makes a community prosperous.
Penn In the News
AI will change work, for better and worse
Sonny Tambe of the Wharton School says that AI is a useful tool for most people, not an existential threat.
Penn In the News
U.S. weighs ban on charging buyers for lender title insurance
Benjamin Keys of the Wharton School says that shifting title insurance costs to lenders won’t solve the current problem with the mortgage market.
Penn In the News
Wharton reclaims top spot in U.S. News MBA rankings, other local schools fall
U.S. News & World Report has ranked the Wharton School as the top MBA program in the nation for 2024.
Penn In the News
Hedge funder famous for his ‘black swan’ strategy says there’s ‘something immoral’ about America’s reliance on debt—and future generations ‘will bear the burden for this’
A 2023 study by the Wharton School found that the U.S. has about 20 years left for corrective action to fix the national debt before it hits 200% of GDP.
Penn In the News
Business schools are now encouraging students to use AI as they race to prepare them for a new job market
Ethan Mollick of the Wharton School is teaching his students to use and understand the capabilities of generative AI.
Penn In the News
Many cancer drugs remain unproven five years after accelerated approval, a study finds
PIK Professor Ezekiel Emanuel says that there should be definitive benefits to cancer drugs five years after their initial accelerated approval.
Penn In the News
How much would you pay to make sure you never sawed off a finger?
PIK Professor Herbert Hovenkamp says that the Consumer Protection Safety Commission deals with problems of safety, not competition implications.